Noxopharm’s Lupus Drug Clears Final Preclinical Hurdle

An update from Noxopharm Ltd. ( (AU:NOX) ) is now available.

Noxopharm Limited announced that its lupus medication, SOF-SKN™, has successfully passed the final in vivo preclinical safety study, paving the way for submission to the Human Research Ethics Committee for the HERACLES clinical trial. This milestone marks a significant step towards exploring the drug’s potential in treating autoimmune diseases, with the company aiming to expand into larger markets such as rheumatoid arthritis and other inflammatory diseases. The global autoimmune disease market is projected to grow significantly, highlighting the potential impact of Noxopharm’s advancements on the industry and stakeholders.

More about Noxopharm Ltd.

Noxopharm Limited is an innovative Australian biotech company focused on discovering and developing novel treatments for cancer and inflammation. The company leverages specialist in-house capabilities and strategic partnerships to build a pipeline of proprietary drugs based on two technology platforms, Sofra™ and Chroma™. Noxopharm also holds a major shareholding in Nyrada Inc, a company specializing in novel small molecule therapies.

YTD Price Performance: -25.81%

Average Trading Volume: 108,168

Technical Sentiment Signal: Buy

Current Market Cap: A$20.16M

For detailed information about NOX stock, go to TipRanks’ Stock Analysis page.